Palacaparib

Palacaparib (AZD9574) is a small-molecule drug developed by AstraZeneca. Its target is PARP (the sponsor names PARP). The sponsor states: An oral PARP inhibitor that blocks PARP enzyme activity, preventing DNA repair in cancer cells, particularly tumours with homologous recombination deficiency. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in ovarian cancer, non-small-cell lung cancer and endometrial cancer. The largest, NCT05797168, plans to enrol 602 participants with primary completion expected 2028-08-04. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.